GS-441524

- **Client Information Leaflet:** GS-441524
- **Formulations**

Oral: 50 mg palatable breakable tablets.**VSP**

- **Action**

Nucleoside analogue that terminates the RNA chain of the viral RNA-dependent RNA polymerase. It acts as an alternative substrate for viral RNA synthesis, resulting in RNA chain termination during viral RNA transcription.

- **Use**
    - Used in cases of confirmed or strongly suspected feline infectious peritonitis.
- **DOSES**
    - **Dogs** Not applicable.
    - **Cats** Minimum doses:
        - Effusive (wet) FIP without ocular or neurological signs: 10–12 mg/kg p.o. q24h.
        - Dry FIP with ocular signs: 15 mg/kg p.o. q24h.
        - Dry FIP with neurological signs: 10 mg/kg p.o. q12h. Some protocols also involve remdesivir.
        - Recommended total treatment duration of 84 days.